Bio-avilability and Bio-equivalence

Bio availability is the rate and extent of active drug absorbed and available for action . Assessment of “interchangeability” between the generic and the innovator product is carried out by a study of bioequivalence (BE). During formulation of new entities bio availability and bio equivalents are also prime parameters. Through the conduct of bioavailability and bioequivalence studies, Generic drug products results on average bioequivalence in drug absorption. 

The top 15 biopharmaceutical products each profits annual revenue of more than $2 billion, with some drugs generating sales of more than $10 billion a year. In 2015 the top NMEs include Pfizer’s Ibrance, J&J’s Darzalex and Gilead’s Genvoya with a cumulative value of $32bn of sales expected in 2020.

  • Physico - Chemical properties affecting Bioavailability
  • Formulation Factors Aaffecting Bioavailability
  • Pharmacokinetics
  • Pharmacodynamics Studies

Related Conference of Bio-avilability and Bio-equivalence

October 18-20, 2018

18th World Pharma Congress

Warsaw, Poland
February 28-March 01, 2019

Global Pharmaceutical & Pharma Industry Conference

Osaka, Japan
March 18-19, 2019

13th International Conference on Biosimilars and Biologics

Amsterdam | Netherlands
August 5-6, 2019

13th Asian Biologics and Biosimilars Congress

Melbourne, Australia

Bio-avilability and Bio-equivalence Conference Speakers

Recommended Sessions

Related Journals

Are you interested in